Comerica Bank Reduces Holdings in Hims & Hers Health, Inc. $HIMS

Comerica Bank decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 19.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,938 shares of the company’s stock after selling 12,808 shares during the period. Comerica Bank’s holdings in Hims & Hers Health were worth $1,594,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HIMS. UMB Bank n.a. increased its stake in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after buying an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Hims & Hers Health during the 1st quarter worth $41,000. Larson Financial Group LLC grew its holdings in Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after acquiring an additional 458 shares in the last quarter. Fifth Third Bancorp grew its holdings in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock worth $46,000 after acquiring an additional 961 shares in the last quarter. Finally, Tsfg LLC acquired a new position in Hims & Hers Health during the 1st quarter worth $46,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 7.2%

NYSE HIMS opened at $44.50 on Thursday. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a 50-day simple moving average of $50.02 and a 200-day simple moving average of $45.56. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The firm has a market capitalization of $10.06 billion, a PE ratio of 55.63, a price-to-earnings-growth ratio of 2.86 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company’s quarterly revenue was up 72.6% on a year-over-year basis. During the same period last year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on HIMS. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Truist Financial decreased their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $38.92.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 17,102 shares of the business’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the transaction, the insider directly owned 278,654 shares of the company’s stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,395,428 shares of company stock valued at $71,753,898. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.